BOSULIF (™) (bosutinib) BOSULIF (bosutinib), indicated for, the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy, and for whom subsequent treatment with imatinib, nilotinib and dasatinib is not clinically appropriate. To read the announcement from Pfizer regarding the...Read More
Health Canada CONDITIONALLY approves BOSULIF – a new medication for chronic myelogenous leukemiaApproval provides new treatment option for Canadians suffering from rare cancer SANTÉ CANADA APPROUVE CONDITIONNELLEMENT L’EMPLOI DE BOSULIF – UN NOUVEAU MÉDICAMENT CONTRE LA LEUCÉMIE MYÉLOÏDE CHRONIQUELes Canadiens bénéficient ainsi d’une nouvelle option de traitement pour un cancer rare Read More
The CML Society of Canada has been invited to provide input to the Pan Canadian Oncology Drug Review regarding the process that will eventually determine whether iClusig will be reimbursed through the various provincial bodies. The Pan Canadian Oncology Drug Review analyzes information from Oncologists, Health Care Economists, Patients and the manufacturers. The outcome is...Read More
The CML Society of Canada is very pleased to be joining forces with over 33 other patient organizations to raise awareness of the inequality and discrimination of cancer patients that exists in Canada today. Canadian Cancer patients face discrimination based on the type of cancer they are diagnosed with and by where they live in...Read More
COVID vaccine information For CML patients living in Quebec, under the age of 60 Statement from the iCMLf for people with CML and COVID-19 Vaccines Read the Expert Panel statement and important advice on CML & COVID-19 If you are a CML patient and you have tested positive for COVID-19, the iCMLf would like to...Read More
COVID-19 case collection and case discussion At present we do not have data on CML patients who have been infected with COVID-19. To help gather CML specific information, the iCMLf is collecting details of CML patients diagnosed with COVID-19.We are collecting both confirmed and suspected cases. For each CML patient with COVID-19 please complete the following...Read More
CML Educational Session Speakers: Susan Branford, David T. Yeung and Susan Branford,David Marin, MD, Francois Xavier Mahon, MD Monitoring after successful therapy for chronic myeloidleukemia – Susan Branford Susan Branford pointed out the importance of continuous monitoring for patients on TKI’s. She stated that early responses to treatment is beginning to become just as important as the...Read More
Included here are terms specifically related to the disease of CML, as well as some other terms which have been used at one time among fellow CMLers.Read More
CML patients under the age of 60 living in Quebec may now have access to the COVID vaccine. Les patients de moins de 60 ans atteints de LMC vivant au Québec peuvent désormais avoir accès au vaccin COVID. Please feel free to speak to your doctor if you would like more information. The COVID vaccine...Read More
We believe in joining our voices with fellow cancer patient organizations as well as other not-for-profit/charitable organizations who dedicate their work to finding better ways to help everyone access affordable, sustainable and safe medicines. Here are three issues we are currently passionate about: Canadian Patients and Health Advocates Support Proposed Changes to the PMPRB and...Read More
